没有缓冲期，没有预警，连格式都像是客服写的内部工单。不足100字的公告，却让整个广告圈一夜未眠。 在服务商的微信群里，消息像炸雷一样炸开了锅。没人会想到，拼多多会以这样"偷摸"的方式暂停 CID。 为什么会在这个节骨眼突然按下暂停键？拼多多在想什么？ 一、 广告行业英文缩写众多，简单介绍下CID。 CID全称是Click ID，简单讲就是一个在点击广告时生成的唯一ID标识，这个ID会被嵌入跳转链路中，并随用户跳转进入交易平台，最终被绑定到用户的 订单上。 7月13日晚上9点，一纸不足百字的通知静悄悄地发出：多多进宝 CID 信息流投放业务暂停，次日零点起立即生效。 前几天，拼多多悄悄干了一件"大事"。 换句话说，CID帮助交易平台打通了"站外找用户—站内看成交—站外继续买"的漏斗回路，是一种轻运营、高效率的冷启动工具。 另外，CID也是电商平台外包"人群精准投放"的一种方式。平台本身不需要训练复杂的广告算法模型，而是把订单回传给抖音、小红书、快手这些内容平 台，让它们的推荐系统负责找对的人、讲对的故事。这对于自身广告能力还不够强的平台来说，是个事半功倍的做法。 所以你会发现，表面上看，是内容平台给交易平台"导 ...

"港交所的铜锣快不够用了。"这句投资者的调侃，正成为港股IPO（首次公开募股）市场火爆最为显性的一面。 7月9日，港交所金融大会堂6面铜锣齐鸣，创下年内上市公司数量纪录，也创下港交所铜锣数量新高，原本在香港各区巡礼展 览的铜锣都被拉回来摆在现场。 当日，峰岹科技（688279.SH）、极智嘉（2590.HK）、讯众通信（2597.HK）、大众口腔（2651.HK）、蓝思科技 （6613.HK）5家公司同日登陆港交所主板，恒生摩根美国股票高入息主动型ETF亦同日上市，金融大会堂首现六锣同鸣。 据万得（Wind）数据，2025年上半年，港股市场的IPO募资额高达1067亿港元，是去年同期的近8倍，重返全球第一。从上市 时间分布来看，5月与6月为上半年新股上市的集中时段，期间共有25家企业完成IPO，占上半年上市总量的58.14%。而2月、4 月分别仅有1家和2家企业实现上市，为上半年上市数量最少的两个月份。 从募资情况来看，实际募资额超过20亿港元的新股有8只，超过10亿港元的有17只。其中，实际募资总额前五名的分别为宁德 时代、恒瑞医药、海天味业、三花智控与蜜雪冰城，募资总额分别为410.06亿港元、113.7 ...

01、特斯拉示好家庭用户 2024年下半年，市场上曾传出特斯拉将会在2025年推出7座版Model Y，当时大家都不以为然。7月16日 晚，特斯拉终于官宣，将在今年秋季推出Model Y L，只不过是六座版。 工信部发布的《道路机动车辆生产企业及产品公告》（第397批）的车辆新产品公示清单显示，Model Y L采用的是三排六座布局，车身长度近5米，轴距超3米，比Model X还长了75毫米。 和目前在售的五座版焕新Model Y最明显的变化是，Model Y L的尾标，在"Y"旁边多了两条斜纹。 除了上述六座SUV，工信部还公示了特斯拉另一款车型"Model 3+"。 还记得2019年8月，特斯拉在国内下架了Model 3的长续航后驱版车型。但据智通财经报道，此次特斯拉 中国将"恢复"Model 3最长续航版本，该车型售价在27万元左右，预计最早于9月上市，有望成为特斯拉 目前最长续航的车型。 02、销量焦虑 曾几何时，市场上的新能源车只有两种，一种是特斯拉，另一种是其他。 综合多家媒体消息，Model Y L由特斯拉上海超级工厂生产，主要在中国市场发售。部分业内人士预 计，Model Y L售价会在40万 ...

Core Viewpoint - China National Pharmaceutical Group (中生制药) has acquired the innovative drug company Lixin Pharmaceutical (礼新医药) for $950 million (approximately 6.8 billion RMB), with the deal being characterized as a high-value acquisition despite initial market skepticism regarding Lixin's product pipeline [1][4]. Group 1: Acquisition Details - The acquisition was completed in a short span of two months, indicating strong mutual interest from both parties [1][4]. - The net cost of the acquisition is effectively reduced to $500 million after accounting for Lixin's cash reserves of $450 million and other operational expenses [4]. - Lixin Pharmaceutical has a strong track record, having raised significant funding and established partnerships with major pharmaceutical companies like AstraZeneca and Merck [1][5]. Group 2: Financial Implications - Lixin's valuation during its last funding round was approximately 2.9 billion RMB, and the acquisition price reflects a significant return for early investors, exceeding 100% [4][5]. - The acquisition is expected to enhance China National Pharmaceutical's revenue from innovative products, which is projected to rise from 16% in 2018 to 42% by 2024 [9]. Group 3: Product Pipeline and Development - Lixin has developed a robust pipeline with eight self-researched innovative drugs currently in clinical trials, including promising candidates like CCR8 monoclonal antibody LM-108 and CLDN18.2 ADC drug LM-302 [6][11]. - The acquisition will bolster China National Pharmaceutical's capabilities in large molecule drug development, particularly in oncology, where it has 36 candidates in clinical development [9][10]. Group 4: Strategic Positioning - The acquisition aligns with China National Pharmaceutical's strategy to transition from traditional pharmaceutical operations to a more innovation-driven model, aiming to launch five innovative products annually over the next three years [9]. - Lixin's integration is seen as a strategic move to enhance R&D capabilities and accelerate the commercialization of innovative drugs in a competitive market [8][11].

2025年来，mRNA领域颇有"复苏"的迹象。6月底，艾伯维宣布斥资21亿美元收购体内CAR-T疗法公司 Capstan Therapeutics；而BioNTech、Moderna等更早入局的企业，也已布局了成熟的mRNA疫苗的药物 设计和递送技术等研发平台，探索肿瘤疫苗等产品的研发，进展快者已进入二期临床阶段。 近两年，BD几乎成为国内创新药企的重要"KPI"。相关数据统计，今年以来，全球肿瘤领域授权交易的 首付款中，来自中国的资产贡献了将近50%的份额。"这说明不同于过去，跨国药企现在已经非常认可 中国创新的价值；第二，也证明了中国的自主创新、成本和效率都达到了一定程度。" 具体到mRNA技术领域，该技术集合了软件式平台、通用型生产平台的优势，具备覆盖从肿瘤到自免、 代谢性疾病、传染病等多种难治性疾病的药物开发能力。作为基因技术，mRNA技术可将药物开发 从"分子筛选"转变为"信息设计"，实现了"信息即药物"，可利用人体自身生成药物，使人体成为为自身 生产药物的"智能工厂。 从过往的案例看，在个性化肿瘤疫苗产品领域，国际大药企之间有过很多交易，比较有代表性的是 Moderna和BioNTech两家的对外 ...

Core Viewpoint - Zhejiang Xinxing Tool Co., Ltd. has initiated its IPO process on the ChiNext board, with a focus on precision CNC tool manufacturing and a projected revenue of 467 million yuan and net profit of 185 million yuan for 2024 [1][3]. Financial Performance - The company expects to achieve revenues of 391 million yuan, 425 million yuan, and 467 million yuan from 2022 to 2024, with net profits of 172 million yuan, 177 million yuan, and 185 million yuan respectively [3][4]. - The gross profit margins are projected to be 58.06%, 57.10%, and 56.49% for the same period, significantly higher than the industry average of 44.93%, 41.51%, and 38.25% [3][4]. Market Position - Xinxing Tool ranks first in sales volume for steel plate drill products among domestic tool manufacturers, as certified by the China Machine Tool Industry Association [3][6]. - The company's products are utilized in major projects such as the Qinshan Nuclear Power Station and the Shanghai Maglev Train project, with key clients including China National Railway and Bosch [3][5]. Research and Development - The company has invested a total of 65.18 million yuan in R&D from 2022 to 2024, representing approximately 5.21%, 5.15%, and 4.90% of its revenue [5][6]. - Xinxing Tool has been granted 146 patents, including 33 invention patents, and has played a role in establishing two national industry standards [5][7]. Ownership Structure - The Zhu Dongwei family controls 92.65% of the company's shares, with Zhu Dongwei serving as the chairman and general manager [8].

Core Viewpoint - The company is facing significant challenges, including a 97% stock price drop, a cumulative loss of 1.2 billion, and the closure of 219 stores in one year, prompting the launch of the "Feng Huan Chao" partner program to empower employees as store partners [1][11][12] Group 1: "Feng Huan Chao" Partner Program - The "Feng Huan Chao" program aims to incentivize frontline employees, with the first batch of 21 core employees becoming partners, focusing on operational managers and store managers [5][7] - The partnership model involves a tripartite shareholding structure among partners, the company, and executives, allowing partners to focus on store performance while the company provides funding and brand support [5][6] - This internal partnership approach is designed to bind talent and activate the organization, transforming employees from executors to decision-makers, thereby enhancing responsibility and loyalty [7][8] Group 2: Market Challenges and Strategic Shifts - The company is navigating a rapidly changing hot pot market, facing challenges from competitors and internal struggles, including a significant decline in the performance of its high-end brand, Coucou [3][10][14] - The company has accumulated losses of 1.183 billion from 2021 to 2024, with a peak loss of 401 million in 2024, largely attributed to the underperformance of Coucou [11] - The company is shifting focus away from the high-end market, which has seen competitors like Haidilao and Banu gaining traction, while it struggles to maintain its customer base [17][18] Group 3: Food Safety and Quality Control - The partner program mandates that all partner stores must integrate into a global supply chain and management system to ensure food safety and service standards, mitigating risks commonly associated with traditional franchise models [12] - Recent complaints about food safety issues highlight the need for stringent quality control measures, reinforcing the importance of the new management structure [12][20] Group 4: Market Position and Future Outlook - The hot pot market is projected to grow, with a significant increase in small hot pot establishments, but the company faces challenges in positioning itself within this competitive landscape [18][19] - The company must prioritize quality and value to regain market share, as competitors are increasingly encroaching on its target demographic with lower-priced offerings [20][21]

这个夏天，来WAIC 2025解锁一场AI科技的沉浸式盛宴。四大主题展馆，3000余件前沿展品、800多家企业同台竞技，7万平方米展区让你一次看尽全球AI 产业的全景演练。 想在这么大的展览里逛得有收获、拍得尽兴，可不仅靠"随便走走"。"Hi! WAIC"智能助手这次化身你的专属策展师，贴心为不同兴趣人群定制私人专属 观展路线。 无论你是硬核技术控、产业应用达人、消费电子爱好者，还是投资创业者，都能找到自己的"宝藏展区"和专属看点。 开发者&技术极客Vibe Coding H1核心技术馆 H1馆揭开AI能力黑盒，谷歌、亚马逊云科技、思科等海外巨头，阿里巴巴、华为、蚂蚁集团等国内大厂，AI六小龙、北斗七星、科创八杰等科创新秀聚 首，全馆集中呈现「国产化突破」「开源繁荣」「基础设施升级」「大模型与算力协同」四大关键词。 · 看点揭秘 在国产化突破方面，华为展示了业界最大规模的"昇腾384超节点真机"，曦智发布全球首款"天枢光电混合计算芯片"，推动光电计算商业落地；安擎推出 EG8420H4服务器是一款全新企业级高性能4U人工智能服务器产品，泽丰聚焦探针卡等半导体测试国产替代，超擎数智则通过XDR交换机展现本土系统 ...

宗庆后家族信托被击穿，340亿遗产争夺战揭开财富传承困局。 2024年5月，一笔108.5万美元的转账从汇丰银行账户中悄然转出，成为宗氏家族百亿遗产争夺战的导火索。 不久后，香港高等法院，一份冰冷的起诉书掀开了这个中国饮料帝国最隐秘的家族伤疤。宗继昌（Jacky Zong）、宗婕莉（Jessie Zong）和宗继盛（Jerry Zong）——三名持美国护照的"宗氏子女"，起诉宗馥莉与一家名为Jian Hao Ventures Limited的公司，要求获得宗庆后生前承诺的每人7亿美元信托权益， 总额21亿美元。 近日，三人又向杭州法院申请调取宗庆后的血液样本进行DNA比对，并要求分割娃哈哈集团29.4%股权（价值超200亿元）。相比于去年12月底对于三人 身份的保留，原告方律师这次直接确认，三人是"宗馥莉同父异母的弟妹"。 这场横跨香港与杭州的诉讼，将娃哈哈集团董事长宗馥莉推上风口浪尖，将"布鞋首富"宗庆后"一妻一女一布鞋"的人设彻底击碎，也将富豪家族的财富传 承问题暴露在大众面前。 这份传说中的21亿美金信托是如何被击穿的？宗庆后的遗产最终可能归属何处？富豪家族们如何通过信托来成功传承自己的财富？ 图片来源 ...

Group 1 - Goldman Sachs predicts that gold prices could reach $4,000 per ounce by mid-2026, with an expected increase to $3,700 by the end of 2024 [3][6] - Central banks globally purchased an average of approximately 77 tons of gold per month from January to May this year, with China being the largest identifiable buyer [3][6] - The COMEX gold futures price has seen a cumulative increase of 27.39% for the entire year of 2024, marking the largest annual increase since 2010 [3] Group 2 - Geopolitical tensions, particularly in the Middle East, are driving investors towards gold as a safe-haven asset, enhancing its appeal amid rising risks [8][9] - The potential for a decline in the value of the US dollar due to high inflation and increasing fiscal deficits could lead to higher gold prices, as gold is typically priced in dollars [9][11] - Many central banks are increasing their gold reserves as part of a strategy to diversify away from the US dollar, which supports the demand for gold and contributes to its price stability [11]